Asset
QUEMLICLUSTAT
ARCUS BIOSCIENCES INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05329766 | phase2 | active_not_recruiting | 2022-06-10 | 2027-01-01 | Arcus Biosciences, Inc. | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies |
| NCT04104672 | phase1 | completed | 2019-11-06 | 2026-07-21 | Arcus Biosciences, Inc. | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies |
| NCT04575311 | phase1 | completed | 2020-10-20 | 2021-09-22 | Arcus Biosciences, Inc. | A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers |
| NCT03677973 | phase1 | completed | 2018-10-16 | 2019-08-19 | Arcus Biosciences, Inc. | A Study to Investigate the Safety of AB680 in Healthy Volunteers |
| NCT04381832 | phase1_2 | completed | 2020-07-07 | 2024-08-30 | Arcus Biosciences, Inc. | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer |
FDA applications (0)
This company has no applications containing this asset.